ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 191 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2018. The put-call ratio across all filers is 1.26 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $271,632 | -93.6% | 170,838 | -74.9% | 0.00% | -95.8% |
Q4 2022 | $4,233,472 | +383.3% | 679,530 | +393.3% | 0.02% | +380.0% |
Q2 2022 | $876,000 | -64.9% | 137,744 | -74.4% | 0.01% | -64.3% |
Q1 2022 | $2,496,000 | -22.2% | 537,856 | -16.2% | 0.01% | -22.2% |
Q4 2021 | $3,210,000 | +3.7% | 642,035 | +150.1% | 0.02% | -10.0% |
Q3 2021 | $3,094,000 | +125.8% | 256,761 | +296.3% | 0.02% | +122.2% |
Q2 2021 | $1,370,000 | +6.1% | 64,794 | +30.5% | 0.01% | -18.2% |
Q4 2020 | $1,291,000 | +236.2% | 49,643 | +670.7% | 0.01% | +57.1% |
Q4 2019 | $384,000 | +48.3% | 6,441 | +15.6% | 0.01% | 0.0% |
Q2 2019 | $259,000 | -94.2% | 5,571 | -91.8% | 0.01% | -92.8% |
Q4 2017 | $4,455,000 | -2.8% | 67,666 | -26.0% | 0.10% | -4.9% |
Q3 2017 | $4,585,000 | -2.2% | 91,480 | -9.7% | 0.10% | -12.8% |
Q2 2017 | $4,689,000 | +131.2% | 101,319 | +76.4% | 0.12% | +138.8% |
Q1 2017 | $2,028,000 | -59.9% | 57,435 | -73.2% | 0.05% | -79.4% |
Q3 2015 | $5,052,000 | – | 214,162 | – | 0.24% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |